Why Endocyte (ECYT) Stock Plummeted to a One-Year Low Today

NEW YORK (TheStreet) -- Endocyte  (ECYT) plummeted more than 60% to a one-year low of $6.50 on Friday after the biopharmaceutical company stopped a late-stage trial of its experimental ovarian cancer drug.

The trial tested Vynfinit (vintafolide) in combination with a chemotherapy drug called pegylated liposomal doxorubicin (PLD) against a combination of PLD and a placebo. The drug did not improve survival rates in subjects without the cancer worsening.

Independent monitors had been reviewing the trial and recommended halting the trial.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Robert W. Baird downgraded the stock to "neutral" in the wake of the news.

The stock was down 62.26% to $6.56 at 11:07 a.m. More than 11 million shares had changed hands, which easily beat the average volume of 1,363,470.

For more on this story, read TheStreet's Adam Feuerstein's article here.

ECYT Chart

ECYT data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock

4 Biotech Stocks Under $10 to Trade for Breakouts

Why Endocyte (ECYT) Stock Is Declining Today